Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$46.1M
Filings
553
Firms Hired
12
Active Period
2005–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Client expense: $970,000 · Firm income: —
Matched citations: H.R. 4030
Policies impacting pharmaceutical distribution and manufacturing: H.R.4780 - USTRx Act
Client expense: $970,000 · Firm income: —
Matched citations: H.R.4780
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $970,000 · Firm income: —
Matched citations: H.R. 5509
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
2026 · third_quarter · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $970,000 · Firm income: —
Matched citations: H.R.8469
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
2026 · third_quarter · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $970,000 · Firm income: —
Matched citations: H.R.8845
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
2026 · third_quarter · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $970,000 · Firm income: —
Matched citations: H.R.9260
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Awareness of sleep disorders, such as Narcolepsy Type 1, Type 2, and Idiopathic Hypersomnia and their impact on mental wellbeing; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $970,000 · Firm income: —
Matched citations: S. 2903
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2026 · third_quarter · Firm: THORN RUN PARTNERS
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $90,000
Matched citations: S. Con. Res. 14
Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R.946
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
2026 · third_quarter · Firm: PENN AVENUE PARTNERS
Regulatory and legislative issues impacting Alkermes. Appropriations. H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client expense: — · Firm income: $80,000
Matched citations: H.R.8469
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Client expense: $930,000 · Firm income: —
Matched citations: H.R. 4030
Policies impacting pharmaceutical distribution and manufacturing: H.R.4780 - USTRx Act
Client expense: $930,000 · Firm income: —
Matched citations: H.R.4780
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $930,000 · Firm income: —
Matched citations: H.R. 5509
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
2026 · second_quarter · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $930,000 · Firm income: —
Matched citations: H.R.8469
Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
2026 · second_quarter · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $930,000 · Firm income: —
Matched citations: H.R.8845
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
2026 · second_quarter · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $930,000 · Firm income: —
Matched citations: H.R.9260
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 5509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; Prescription Drug User Fee Agreement implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027; H.R.9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027; H.R.8845 - Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027
Client expense: $930,000 · Firm income: —
Matched citations: S. 2903
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
2026 · second_quarter · Firm: THORN RUN PARTNERS
Build Back Better: S. Con. Res. 14, A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2022 and setting forth the appropriate budgetary levels for fiscal years 2023 through 2031.
Client expense: — · Firm income: $90,000
Matched citations: S. Con. Res. 14
Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
2026 · second_quarter · Firm: PENN AVENUE PARTNERS
Regulatory and legislative issues impacting Alkermes. Appropriations. H.R.8469 - Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes.
Client expense: — · Firm income: $80,000
Matched citations: H.R.8469
Medicare/Medicaid issues. Medicaid drug rebate program. Prescription drug pricing, including MDRP Substance Use Disorder Policy. Implementation of Inflation Reduction Act of 2022. H.R.946: ORPHAN Cures Act. Provide strategic counsel and advocate on issues related to the biopharmaceutical industry generally, and Alkermes, Inc. specifically. Provide guidance and advice regarding mental health, public health and regulatory reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R.946
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · first_quarter · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
Client expense: $1,030,000 · Firm income: —
Matched citations: H.R. 1
Expand funding and flexibility to address all substance use disorders: H.R. 4030 - Treatment Continuity Act of 2025
Client expense: $1,030,000 · Firm income: —
Matched citations: H.R. 4030
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
2026 · first_quarter · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
Client expense: $1,030,000 · Firm income: —
Matched citations: H.R. 5371
Consolidated Appropriations Act, 2026
2026 · first_quarter · Firm: ALKERMES, INC.
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
Client expense: $1,030,000 · Firm income: —
Matched citations: H.R. 7148
Ensure patient access to appropriate medications by limiting the unnecessary use of utilization management policies, including H.R. 55509/S. 2903 the Safe Step Act; Awareness of need for transparency and patient access within the 340B program; PDUFA implementation and efficiency improvements at the FDA; Policies impacting pharmaceutical development, reimbursement, and patient access and cost: H.R. 5371 - Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026; H.R. 7148 - Consolidated Appropriations Act, 2026; H.R. 1 - One Big Beautiful Bill Act;
Client expense: $1,030,000 · Firm income: —
Matched citations: S. 2903
Source: Senate LDA